Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome

Access Programs

Disease Information

Descriptive Information
Brief Title † Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome
Official Title † Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome
Brief Summary The aim of this study is to study the effects of GH on body composition, lipid and glucose metabolism, physical performance and safety aspects in adults with PWS.The patients are randomized to either GH or placebo the first year of the study, subsequently followed by two years of GH treatment. the study is performed in Norway, Sweden and Denmark.
Detailed Description OBJECTIVE(S): Prader Willi syndrome (PWS) is a multi-symptomatic genetic disorder associated with abnormalities in the growth hormone (GH)-insulin-like-growth factor (IGF)-I axis and in the body composition. GH treatment is a registered indication in children with PWS, and improves growth rate and body composition. One pilot study in adult patients with clinical PWS has shown beneficial effects on body composition without simultaneous significant side effects. The aim of the present study is to evaluate the effects of GH treatment on body composition, muscle function and quality of life in PWS adults. TRIAL DESIGN: The study will be an investigator initiated and investigator sponsored multinational and multi-centre trial, including centres in Norway, Sweden and Denmark. Within each centre patients will be randomised (double blind) to one year treatment with daily injections of GH or placebo (efficacy), followed by a two year observation period on GH treatment (safety). TRIAL POPULATION: Twenty patients from each centre are included in the study. The patients need a genetically verified diagnosis and should be between 18 and 40 years old. Patients are excluded if GH treatment has been given within the last two years, if they have a malignancy or other serious diseases, in particular severe respiratory diseases. ASSESSMENTS: Effect is evaluated primarily as changes in body composition, activity of daily living and quality of life. SAFETY: Before starting in the study all patients will be examined for tonsillary hypertrophy and sleep apnoea. Oral Glucose Tolerance Tests will be performed regularly. TRIAL PRODUCT(S): During the initial 4 weeks of the placebo-controlled study phase patients will be treated with sc injections of GH (Norditropin Simplexx) in the evening with doses of 0.3 mg/day respectively 0.4 mg/day if BW is below or above 100 kg. Thereafter doses will be increased to 0.6 mg/day (0.8 mg/day) and maintained fixed for 11 months. During the following 24 months open phase doses will be individually titrated.
Study Phase N/A
Study Type † Interventional
Study Design † Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary Outcome Measure † Changes in body composition (lean body mass and fat mass) measured by dual energy X-ray absorptiometry (DXA)
Secondary Outcome Measure † Bone mineral density measured by DXA
Condition † Prader-Willi Syndrome
Intervention † DrugNorditropin SimpleXx
Study Arms / Comparison Groups Norditropin SimpleXx 0.3 mg/day or 0.4 mg/day if bodyweight was below or above 100 kg,for 4 weeks, 0.6 mg/day or 0.8 mg/day, for 11 months. Placebo Placebo for 12 months
Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status † Drug
Estimated Enrollment † 46
Start Date † April 2005
Completion Date March 2010
Primary Completion Date March 2010
Eligibility Criteria † Inclusion Criteria: - Genetically verified PWS diagnosis (by methylation and FISH test.) - Between 18 and 50 years old - Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the treatment of the subject.) Exclusion Criteria: - Known or suspected allergy to GH preparation. - Previous participation in this trial. - GH treatment within the last 1 years - Malignancy or other serious diseases (ex severe cardiovascular diseases, severe infections) - Sexhormone treatment initiated within the last year - Pregnancy - Untreated respiratory impairment, untreated sleep apnoea or untreated respiratory infection.
Gender Both
Ages 18 Years - 50 Years
Accepts Healthy Volunteers No
Contacts ††
Location Countries † Denmark
Administrative Information
NCT ID † NCT00372125
Organization ID CH1234
Secondary IDs ††
Responsible Party Principal Investigator
Study Sponsor † Karolinska University Hospital
Collaborators †† Novo Nordisk A/S
Investigators † Principal Investigator: Charlotte Hoybye, Dr., Department of Endocrinology and Diabetology, Karolinska Hospital
Information Provided By
Verification Date April 2015
First Received Date † September 5, 2006
Last Updated Date April 6, 2015
† Required WHO trial registration data element.
†† WHO trial registration data element that is required only if it exists.
Find a Clinical Trial
Related Videos
by Harish Ravi
Free Newsletter